Abstract
Today, low molecular weight heparins belong to most commonly used drugs in the prophylaxis or treatment of venous thromboembolism, both in surgical and in nonsurgical specialties. They are also being introduced in the treatment of acute coronary syndrome.
They have a number of clear advantages compared to unfractionated heparins, and do not have to be monitored with laboratory tests because of their stable antithrombotic effect in most cases.